Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys, Astellas Extend Antibody Library License

NEW YORK (GenomeWeb News) – The German antibody developer Morphosys has extended an agreement with Astellas Pharma that allows the Japanese pharmaceutical company to use the HuCAL Gold antibody library for therapeutics development for four more years.
The companies extended an agreement they signed in March 2007 that gives Astellas access to the antibody library at its Tsukuba, Japan, facility through 2012, and they renewed an option for commercialization and development of therapeutic antibodies.
Under the agreement, MorphySys will receive annual user fees for the HuCAL platform and may receive exclusive license fees, milestones, and royalty payments from any therapeutics Astellas markets that were derived from MorphySys’ technology.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more